• annexin A1;
  • gastric cancer;
  • peritoneal Dissemination


  1. Top of page
  2. Abstract

Annexin A1 (ANXA1) is a multifunctional molecule, which mediates various important physiologic processes depending on its subcelluar localization. The purpose of this study was to investigate the expression of ANXA1 level and its subcellular localization in paired clinical samples of gastric adenocarcinoma and adjacent normal counterpart. The study also assesses the clinical significance of ANXA1 subcelluar localization in gastric adenocarcinoma. A total of 104 paired resected gastric adenocarcinoma and corresponding normal specimens were collected in this study. Expression of ANXA1 was examined by immunohistochemical staining. Both cytoplasmic and nuclear ANXA1 expression levels and their correlation with clinicopathological parameters were assessed. ANXA1 protein expression was positive in 72 of 104 (69.2%) normal tissues and 47 of 104 (45.2%) gastric adenocarcinoma tissues. ANXA1 staining was predominantly localized in the cytoplasm in all 72 ANXA1-positive normal specimens, whereas 12 ANXA1-positive gastric adenocarcinoma specimens showed positive nuclear staining. The positive nuclear staining correlated well with serosal invasion, peritoneal dissemination and TNM stage. Cases with positive nuclear staining presented more peritoneal dissemination (41.7%, 5/12) than those with negative nuclear staining (8.7%, 8/92; P = 0.007). A logistic regression model revealed that positive ANXA1 nuclear staining had an independent association with peritoneal dissemination (P = 0.039; hazards ratio, 9.499; 95% confidence interval, 1.159–77.815). These results indicated that ANXA1 is expressed in both gastric adenocarcinoma and normal tissues. In gastric adenocarcinoma tissues ANXA1 is expressed both in cytoplasm and nucleus and its nuclear localization correlates with advanced disease stage and peritoneal dissemination. Anat Rec 293:1310–1314, 2010. © 2010 Wiley-Liss, Inc.

Gastric cancer is the second most common cancer worldwide and peritoneal dissemination is one of the most important prognostic factors in patients with gastric cancer (Dicken et al., 2005; Hohenberger and Gretschel, 2004). However, the molecular mechanism causing peritoneal dissemination of cancer cells is still poorly understood and there have been no valid markers indicating the development of peritoneal dissemination.

The anti-inflammatory protein, Annexin A1 (ANXA1) is the characterized member of the annexin family of proteins able to bind to cellular membranes in a calcium-dependent manner. Previous studies have shown that ANXA1 inhibits cytosolic phospholipase 2 activity and arachidonic acid generation, which is related to its anti-inflammatory and antiproliferative functions. Furthermore, ANXA1 expression in tumor cells has been investigated in vitro and in vivo in the cancer of head and neck (Garcia et al., 2004), liver (de Coupade et al., 2000), esophagus (Xia et al., 2002), lung (Lu et al., 2008), breast (Cao et al., 2008), stomach (Yu et al., 2008), and prostate (Siang et al., 2006). Correlation of ANXA1 expression with tumorigenesis and advancement of some types of cancer and patients' survival have also been reported (Paweletz et al., 2000, Wang et al., 2006). ANXA1 is a soluble protein and localized in the cytoplasm of cells, moving to membrane when calcium level is elevated and also can translocate into nucleus upon stimulation. Treatment of A549 and HeLa cells with heat, hydrogen peroxide, or sodium arsenite resulted in an increase in ANXA1 and translocation from the cytoplasm to the nucleus (Rhee et al., 2000). Recently, it is reported that nuclear staining of ANXA1 is a significant predictor of poor overall survival in oral squamous cell carcinoma (OSCC) (Lin et al., 2008). Therefore, different subcellular localizations of ANXA1 may contribute to different functions in a condition-specific manner.

The objective of the current study was to investigate the ANXA1 protein expression level and the subcellular localization in gastric adenocarcinoma specimens and to evaluate the clinical significance of ANXA1 expression by its correlation with clinicopathological parameters. To our knowledge, no studies have been performed to characterize the expression of ANXA1 in subcellular compartments in clinical gastric adenocarcinoma specimens previously.


  1. Top of page
  2. Abstract

Case Selection

Paired specimens of gastric adenocarcinoma and corresponding normal tissues were obtained from 104 patients who underwent surgical resection of gastric adenocarcinoma in the Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University between July 1995 and March 2007, with informed consent under the guideline of Hospital Ethics Committee. The patients comprised 68 males and 36 females aged from 38 to 88 years old (mean = 67.5 years old), including 91 R0 (radical operation) patients and 13 peritoneal carcinomatosis patients. None of the patients received any anti-cancer treatment before surgery. Correlation between expression of ANXA1 and clinicopathologic parameters including age, sex, pathological Tumor-Node-Metastasis (pTNM) (Hermanek et al., 1987), peritoneal dissemination and lymph node metastasis was evaluated.

Immunohistochemical Analysis of ANXA1

An Immunohistochemical analysis of ANXA1 was performed on formalin-fixed, paraffin-embedded sections of surgically resected specimens. The slides were deparaffinized in xylene and dehydrated in a graded ethanol series. Endogenous peroxidase was blocked with 0.3% H2O2 in methanol for 10 min. The slides were immersed in 10 mM citric buffer solution (pH 6.0) for antigen retrieval. Nonspecific binding was blocked by preincubation with 10% fetal calf serum in PBS with 0.01% sodium azide. Blocking serum was drained off, and the slides were separately incubated with antibody against ANXA1 (mouse monoclonal, Santa Cruz; 1:200) in a humidified chamber for 1 hr. After washing three times with PBS, the slides were incubated with the EnVision-HRP complex (undiluted, DAKO) for 30 min. The slides were visualized with diaminobenzidine (DAKO Corp.) and counterstained with hematoxylin. For negative controls, the primary antibody was replaced with phosphate buffered saline. Positive controls included gastric or colonic carcinomas tissue known to exhibit high levels of ANXA1 expression.

All the slides were examined and scored independently by two investigators. Expression of ANXA1 was assessed as overall expression and subcellular distribution in the nucleus and cytoplasm. Immunoreactivity was evaluated by determining the percentage of positive cells in each core and then taking the average of three cores. High expression of ANXA1 was defined as staining of ≥25% of cells, low expression was defined as staining of <25% of cells, and negative staining was defined as no staining of any cells.

Statistical Analysis

All statistical analyses were performed using the statistical program SPSS 15.0 for windows (SPSS, Chicago, IL, USA). Two-tailed chi-square test and the two-tailed t-test were used to evaluate association between ANXA1 expression and clinicopathologic factors. The association of ANXA1 nuclear staining and the peritoneal dissemination was assessed by both correlation test and curvilinear regression. Logistic regression was used to determine the independent risk factors for peritoneal dissemination. The level of significance was set for P < 0.05.


  1. Top of page
  2. Abstract

ANXA1 Expression and Clinicopathologic Parameters

ANXA1 protein expression was positive in 72 of 104 (69.2%) normal tissues and 47 of 104 (45.2%) gastric adenocarcinoma tissues. ANXA1 staining was predominantly localized in the cytoplasm in all 72 ANXA1-positive normal specimens. In gastric adenocarcinoma tissues, 45 (43.3%) specimens showed positive ANXA1 cytoplasmic staining, and in addition, 10 specimens also showed positive ANXA1 nuclear staining. There were only two gastric adenocarcinoma tissues that showed positive ANXA1 nuclear staining, which made a total of 12 (11.5%) gastric adenocarcinoma specimens in the group of positive ANXA1 nuclear staining (Fig. 1). In the tumor specimens, the levels of cytoplasmic staining of ANXA1 were decreased, whereas an increase in nuclear staining of ANXA1 was observed (Table 1). The correlation between ANXA1 nuclear and cytoplasmic staining in the adenocarcinoma specimens with clinicopathological parameters of 104 gastric cancer patients are shown in Table 1. ANXA1 nuclear staining correlates with tumor size, peritoneal dissemination, and TNM stage. However, no difference was found between positive and negative nuclear staining groups regarding sex, age, depth of invasion, node involvement, differentiation, and location. The decrease in ANXA1 cytoplasmic staining in gastric cancer was not associated with any clinicopathologic parameters either.

thumbnail image

Figure 1. Immunohistochemical analysis of ANXA1 expression in gastric adenocarcinomas (200×). a. ANXA1 cytoplasmic staining observed in >25% of tumor cells. b. Negative expression ANXA1 in tumor cells. c. ANXA1 nuclear staining observed in >25% of tumor cells. Arrows show ANXA1 nuclear staining. d. ANXA1cytoplasmic staining observed in >25% of normal tissue cells. e. Negative expression ANXA1 in normal tissue cells.

Download figure to PowerPoint

Table 1. Correlation between adenocarcinoma tissue and corresponding normal tissue in gastric adenocarcinoma patients
 Cytoplasm ANXA1aNuclear ANXA1
  • a

    Cytoplasmic ANXA1 staining of ≥25% of cells was scored as 2, staining of <25% of cells was scored as 1, and absence of staining was scored as 0 (P < 0.001; chi-square test).

Tumor tissue59(56.7)38(36.5)7(6.8)92(88.5)12(11.5)
Normal tissue32(30.8)47(45.2)25(24.0)104(100)0

ANXA1 Protein Nuclear Staining and Peritoneal Dissemination

There were 13 gastric adenocarcinoma patients with peritoneal dissemination enrolled in this study, with five in positive ANXA1 nuclear staining group (totally 12) and eight in negative ANXA1 nuclear staining group (including negative ANXA1 staining, totally 92). The proportion of patients with peritoneal dissemination in positive nuclear ANXA1 staining group (5 of 12, 41.7%) is much higher than those in negative nuclear ANXA1 staining group (8 of 92, 8.7%) (P = 0.007; Table 2). In univariate analysis, ANXA1 protein nuclear staining, poor differentiation, large primary tumor size, serosal invasion, and lymph node metastasis were associated with peritoneal dissemination. When a logistic regression analysis was performed, ANXA1 nuclear staining, poor differentiation, and lymph node metastasis were associated with peritoneal dissemination (P = 0.039, 0.007, 0.013, respectively, Table 3).

Table 2. Comparison of clinicopathologic features in gastric cancer patients
 Nuclear ANXA1
Negative (n = 92)Positive (n = 12)P-value
Age56.0 ± 12.055.6 ± 11.40.901
Gender  1.000
Location  0.275
 Upper body or whole18(19.6)4(33.3) 
 Lower or middle body74(80.4)8(66.7) 
Tumor differentiation  0.172
Tumor size  0.026
 >4 cm37(40.2)1(8.3) 
 ≤4 cm49(53.3)10(83.4) 
Tumor size data lost6(6.5)1(8.3) 
Node invasion  0.052
Peritoneal dissemination  0.007
TNM  0.011
 Stage I/II44(47.8)1(8.3) 
 Stage III/IV48(52.2)11(91.7) 
Table 3. Univariate and multivariate analyses of peritoneal dissemination by logistic regression
 Univariate analysis P-valueMultivariate analysis
Age (>55 vs. ≤55)0.378 0.574
Gender (male vs. female)0.757 0.647
Cytoplasm ANXA10.822 0.674
Tumor location0.125 0.985
Tumor size (≥ 4 cm vs. <4 cm)0.006 0.402
Serosal invasion0.001 0.298
Nuclear ANXA10.0069.499 (1.159–77.815)0.039
Tumor differentiation0.0226.708 (1.673–26.903)0.007
Lymph node metastasis<0.0017.061 (1.520–32.796)0.013


  1. Top of page
  2. Abstract

Annexins are a family of structurally related, calcium-dependent phospholipid binding proteins, which have been proposed to be involved in diverse cellular processes, including phospholipase A2 inhibition, adhesion, exocytosis, and interaction with cytoskeletal proteins (Raynal and Pollard et al., 1994). ANXA1 is a substrate for the epidermal growth factor (EGF)-stimulated tyrosine kinase and is postulated to be involved in mitogenic signal transduction. It is also the substrate for platelet derived growth factor, insulin and hepatocyte growth factor/scatter factor receptor tyrosine kinases (Rothhut et al., 1997). Despite of these known functions, however, other biological functions of ANXA1 still need to be investigated.

Some studies have shown ANXA1 cytoplasm staining correlation with esophageal and esophagogastric junction adenocarcinoma patients' survival (Wang et al., 2006), and loss of ANXA1 expression correlated with gastric cancer patients' poor survival rates (Yu et al., 2008). A more recent study evaluating the prognostic significance of nuclear staining of ANXA1 in OSCC patients showed a lower overall survival, whereas changes in ANXA1 expression levels and decrease of ANXA1 membranous staining in OSCC may not be involved in oral carcinogenesis (Lin et al., 2008). Upregulation of ANXA1 was also observed in multidrug resistant K562 cells (Zhu et al., 2009). In addition, it has been suggested that ANXA1 nuclear translocation participates in the regulation of cellular proliferation (Alldridge and Bryant, 2003; Alves et al., 2008; Gerke and Moss, 2003), and treatment of cells with heat, hydrogen peroxide, sodium arsenite, and EGF resulting in translocation of ANXA1 from the cytoplasm to the nucleus (Rhee et al., 2000). Therefore, we postulated that the different subcellular distribution of ANXA1 may also contribute to tumorigenesis and progression in gastric cancer.

In the current study, no correlation between overall ANXA1 expression and patients' survival was observed. We analyzed the correlation of both cytoplasmic and nuclear expression of ANXA1 with different clinicopathological parameters. Nuclear ANXA1 expression was associated significantly with tumor size, peritoneal dissemination, and TNM stage. However, cytoplasmic ANXA1 expression did not correlate with any of these pathologic parameters.

In this study, peritoneal dissemination was noted in 13 (12.5%) of 104 patients with gastric cancer. More than one-third of these patients had nuclear staining of ANXA1 (5 of 13 patients). Because patients with nuclear staining of ANXA1 had a significantly higher rate for peritoneal dissemination than patients without nuclear (41.7% vs. 8.7%, respectively; P = 0.007), the nuclear staining of ANXA1 may likely be associated with poor prognosis. Based on these data, we propose that ANXA1 nuclear staining correlates with advanced disease and peritoneal dissemination. Although it is not yet clear why ANXA1 nuclear localization correlates with the advanced disease stage and peritoneal dissemination in patients with gastric cancer, there exist some underlying clues. Recently, it is hypothesized that ANXA1 nuclear translocation reflects the activity of oncogenic tyrosine kinases, such as EGF receptor family (EGFR) and c-Met (Lieto et al., 2008, Rhee et al., 2000, Zeng et al., 2008). Overexpressions of the EGFR, Her-2 and Her-3, have been frequently detected in gastric cancer and are thought to be a recognized indicator of poor prognosis (Moutinho et al., 2008, Poller et al., 1992). These finding may provide useful information for further investigation on the role of nuclear localization of ANXA1 in gastric adenocarcinoma.

In this study, correlation between positive ANXA1 nuclear staining and peritoneal dissemination was established; however, there were also seven positive ANXA1 nuclear staining specimens in patients without peritoneal dissemination. Because of the multiple alterations of upstream and downstream pathways affecting ANXA1 expression and subcellular localization, ANXA1 should be recognized as one of the multiple factors, which correlate with gastric adenocarcinoma peritoneal dissemination but exceptions may exist.

Although the exact roles ANXA1 plays and the underlying mechanisms remain to be elucidated, recent works by other researchers provide helpful clues. One study showed that reduced ANXA1 protein level by siRNA led to a significant decrease of melanoma cell invasion, and ANXA1 might enhance melanoma dissemination through formyl peptide receptors (Rondepierre et al., 2009). In another investigation on global screening of protein profiles, ANXA1 is also proposed to play an important role in genesis, progression, recurrence, and metastasis of lung squamous cell carcinoma (Nan, et al. 2009). A more recent work utilizing ANXA1-knockout mice model showed that ANXA1 plays important roles in tumor growth, metastasis, angionesis, and wound healing (Yi, et al., 2009).

In summary, our results showed that ANXA1 is extensively expressed in normal gastric tissues and decreased expression were observed in gastric adenocarcinoma tissues. Compared with negative nuclear staining of ANXA1 in corresponding normal tissue, positive nuclear staining of ANXA1 presented in gastric cancer tissue correlates with advanced disease stage and peritoneal dissemination. Alteration of ANXA1 subcellular distribution may be explored further for its value in monitoring the progress of gastric cancer and predicting patients' outcome and prognosis.


  1. Top of page
  2. Abstract
  • Alldridge LC, Bryant CE. 2003. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res 290: 93107.
  • Alves VA, Nonogaki S, Cury PM, Wünsch-Filho V, de Carvalho MB, Michaluart-Júnior P, Moyses RA, Curioni OA, Figueiredo DL, Scapulatempo-Neto C, Parra ER, Polachini GM, Silistino-Souza R, Oliani SM, Silva-Júnior WA, Nobrega FG, Tajara EH, Zago MA; Head and Neck Genome Project/GENCAPO. 2008. Annexin A1 subcellular expression in laryngeal squamous cell carcinoma. Histopathology 53: 715727.
  • Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. 2008. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16: 530534.
  • Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. 2005. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 2739.
  • de Coupade C, Gillet R, Bennoun M, Briand P, Russo-Marie F, Solito E. 2000. Annexin 1 expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. Hepatology 31: 371380.
  • Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, Suarez Nieto C, Rodrigo JP. 2004. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 164: 7379.
  • Gerke V, Moss SE. 2003. Annexins: from structure to function. Physiol Rev 82: 331371.
  • Hermanek P, Scheibe O, Spiessl, B, Wagner, G. 1987. TNM classification of malignant tumors: the new 1987 edition. Rontgen Blatter 40: 200.
  • Hohenberger P, Gretschel S. 2004. Gastric cancer Lancet 362: 305315.
  • Lu QY, Jin YS, Zhang ZF, Le AD, Heber D, Li FP, Dubinett SM, Rao JY. 2008. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab Invest 87: 456465.
  • Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, Chiang CP, Kuo MY. 2008. Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol 97: 544550
  • Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. 2008. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15: 6979.
  • Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. 2008. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 8: 10.
  • Nan Y, Yang S, Tian Y, Zhang W, Zhou B, Bu L, Huo S. 2009. Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy. Med Oncol 26: 215221.
  • Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF, III. 2000. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60: 62936297.
  • Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD, Mayer RJ. 1992. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. J Pathol 168: 275280
  • Rhee HJ, Kim GY, Huh JW, Kim SW, Na DS. 2000. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 267: 32203225.
  • Raynal P, Pollard HB. 1994. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1197, 6393.
  • Rondepierre F, Bouchon B, Papon J, Bonnet-Duquennoy M, Kintossou R, Moins N, Maublant J, Madelmont JC, D'Incan M, Degoul F. 2009. Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination. Biochim Biophys Acta 1794: 6169.
  • Rothhut B. 1997. Participation of annexins in protein phosphorylation. Cell Mol Life Sci 53: 522526
  • Siang CH, Tunoda T, Whang YE, Tyson DR, Ornstein DK. 2006. The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. Prostate 66: 14131424.
  • Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT. 2006. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 12: 45984604.
  • Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, Han YL, Chen BS, Wei F, Qian XH, Cai YY, Shen Y, Wu M, Wang MR. 2002. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 21: 66416648.
  • Yi M, Schnitzer JE. 2009. Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc Natl Acad Sci USA 106: 1788617891.
  • Yu G, Wang J, Chen Y, Wang X, Pan J, Li Q, Xie K. 2008. Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer. Clin Exp Metastasis 25: 695702.
  • Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT, IV, D'Alessio M, Barany F, Paty PB. 2008. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 265: 258269.
  • Zhu FJ, Wang Y, Zeng S, Fu XY, Wang LB, Cao J. 2009. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS 13: 467476.